{"filing":{"accession_number":"0001658247-26-000052","cik":"0001658247","ticker":"CRNX","company_name":"Crinetics Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"crnx-20260803.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1658247/000165824726000052/crnx-20260803.htm"},"events":[{"id":23446,"run_id":21197,"accession_number":"0001658247-26-000052","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"summary":"The filing discloses Q2 2026 financial results for the period ended June 30, 2026, including revenue of $25.1 million (with $24.0 million in product revenue from PALSONIFY), operating expenses, and net loss of $120.9 million. However, the press release is dominated by the announcement of Vertex's acquisition of Crinetics for $85.00 per share ($10.0 billion total equity value), which is the lead headline and primary business development. While Item 2.02 technically covers earnings results, the material event here is the M\u0026A transaction, not the earnings themselves.","company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23667,"accession_number":"0001658247-26-000052","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses Q2 2026 financial results for the period ended June 30, 2026, including revenue of $25.1 million (with $24.0 million in product revenue from PALSONIFY), operating expenses, and net loss of $120.9 million. However, the press release is dominated by the announcement of Vertex's acquisition of Crinetics for $85.00 per share ($10.0 billion total equity value), which is the lead headline and primary business development. While Item 2.02 technically covers earnings results, the material event here is the M\u0026A transaction, not the earnings themselves.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:32:21.852251+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23667,"accession_number":"0001658247-26-000052","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The filing discloses Q2 2026 financial results for the period ended June 30, 2026, including revenue of $25.1 million (with $24.0 million in product revenue from PALSONIFY), operating expenses, and net loss of $120.9 million. However, the press release is dominated by the announcement of Vertex's acquisition of Crinetics for $85.00 per share ($10.0 billion total equity value), which is the lead headline and primary business development. While Item 2.02 technically covers earnings results, the material event here is the M\u0026A transaction, not the earnings themselves.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:32:21.852251+00:00","company_name":"Crinetics Pharmaceuticals, Inc.","ticker":"CRNX","filing_date":"2026-08-03"}]}